✦ LIBER ✦

High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer

✍ Scribed by George Somlo; James H. Doroshow; Stephen J. Forman; Lucille A. Leong; Kim A. Margolin; Robert J. Morgan Jr.; James W. Raschko; Steven A. Akman; Chul Ahn; Irena Sniecinski

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 901 KB
Volume: 73
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940101)73:1<125::aid-cncr2820730122>3.0.co;2-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose doxorubicin, etoposide, and cy

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer

✍ George Somlo; James H. Doroshow; Stephen J. Forman; Lucille A. Leong; Kim A. Mar 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 780 KB

P53 is the strongest predictor of surviv

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen

High-dose mitoxantrone and cyclophospham

High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma : A Phase II multicentric trial

✍ Jose Luis Pérez-Gracia; Ramon Colomer; Emilio Esteban; Ramón Barceló; Manuel Ben 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

Four versus six courses of a dose-escala

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma

✍ Nobert Schmitz; Marita Kloess; Marcel Reiser; Wolfgang E. Berdel; Bernd Metzner; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB

Erratum: Milano GM, Cozza R, Ilari I, et

Erratum: Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors: The Bambino Gesù Children's Hospital experience. Cancer. 2006;106(8):1838–45.

📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 1 views